• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Expert Review of Molecular Diagnostics >Molecular and clinicopathological markers of prognosis in breast cancer
【24h】

Molecular and clinicopathological markers of prognosis in breast cancer

机译：乳腺癌预后的分子和临床病理标志

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

A vast body of research in breast cancer prognostication has accumulated. Yet despite this, patients within current prognostic categories may have significantly different outcomes. There is a need to more accurately divide those cancer types associated with an excellent prognosis from those requiring more aggressive therapy. Gene expression array studies have revealed the numerous molecular breast cancer subtypes that are associated with differing outcomes. Furthermore, as next generation technologies evolve and further reveal the complexities of breast cancer, it is likely that existing prognostic approaches will become progressively refined. Future prognostication in breast cancer requires a morphomolecular, multifaceted approach involving the assessment of anatomical disease extent and levels of protein, DNA and RNA expression. One of the major challenges in prognostication will be the integration of potential assays into existing clinical systems and identification of appropriate patient subgroups for analysis.
机译：乳腺癌预后方面的大量研究已经积累。尽管如此，当前预后类别中的患者可能会有明显不同的结果。需要更准确地将那些预后良好的癌症与需要更积极治疗的癌症分开。基因表达阵列研究已经揭示了与不同结果相关的众多分子乳腺癌亚型。此外，随着下一代技术的发展并进一步揭示乳腺癌的复杂性，现有的预后方法可能会逐渐完善。乳腺癌的未来预后需要采取一种多分子，多方面的方法，包括评估解剖学疾病的程度以及蛋白质，DNA和RNA表达的水平。预后的主要挑战之一是将潜在的检测方法整合到现有的临床系统中，并确定合适的患者亚组以进行分析。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号